Abstract

Objective To retrospectively analyze the therapeutic effect and adverse reactions of lenalidomide combined with cyclophosphamide and low-dose dexamethasone (RCD) in the treatment of multiple myeloma (MM). Methods Forty-five patients with MM was divided into treatment group (25 cases) and control group (20 cases) according to non-randomized concurrent control method: the former was treated by RCD, and the latter accepted melphalan combined with prednison and thalidomide (MPT). Results The overall response rates (ORR) for the treatment group and the control group were 84.0%(21/25) and 65.0%(13/20)respectively (P > 0.05), and high quality response (CR + VGPR) rates were 64.0%(16/25) and 30.0%(6/20) respectively (P<0.05). The relapse rates and 3-year overall survival rates were 24.0%(6/25) and 55.0%(11/20), 76.0%(19/25) and 45.0%(9/20), respectively (P<0.05). Compared with those of the control group, the incidence of thrombopenia and neutropenia was higher, and treatment-related toxicities were lower in treatment group (P<0.05). Conclusions RCD may be more effective, and adverse reactions can be tolerated. The therapy method is worthy to be recommended. Key words: Multiple myeloma; Pharmacotherapy; Lenalidomide; Cyclophosphamide; Dexamethasone

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.